Volume 28, Issue 1 (3-2021)                   RJMS 2021, 28(1): 0-0 | Back to browse issues page

Research code: ندارد
Ethics code: ندارد
Clinical trials code: ندارد

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

zare-mirzaie A, achak F, babaheidarian P. Evaluating relation of CD133 expression in colorectal adenocarcinoma and clinicopathlogic findings. RJMS. 2021; 28 (1)
URL: http://rjms.iums.ac.ir/article-1-6212-en.html
iran university of medical sciences , pegibh@gmail.com
Abstract:   (266 Views)
 Background After proposing of cancer stem cell hypothesis in recent years numerous studies have been done on various tumor markers with the aim of finding a molecule characterizing the cancer stem cell having prognostic and probably therapeutic value among which CD133 has more or less shown this property in different kinds of cancers..
 Material and methods CD133 expression in 137 patients with colorectal adenocarcinoma treated by surgery alone was assessed by immunohistochemical staining. Frontline   infiltrative tumor border was assessed and clinical correlation with CD133 expression was investigated
Results With cut off point 5% in CD133 staining, 28 tumors (20.4%) were positive and the pattern was exclusively membranous luminal .Among various clinicopathological features, only tumor grade had statistical correlation with CD133 which means that   none of the high grade tumors stain with this immunohistochemical marker 
Conclusion In comparison to other studies, it seems logical that before interpreting staining results, the cut off point and methods should be standardized. In this situation treatment with monoclonal antibody (target therapy) could be a choice in near future as an adjunctive modalities
     
Type of Study: Research | Subject: Pathology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2021 All Rights Reserved | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb